VX 440

Drug Profile

VX 440

Alternative Names: VX-440

Latest Information Update: 05 Apr 2017

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Class
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Ion channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 23 Feb 2017 Vertex Pharmaceuticals has patent protection for VX 440 in USA and countries outside USA (Vertex Pharmaceuticals form 10-K, filed in February 2017)
  • 08 Jan 2017 VX 440 receives Fast Track designation for Cystic fibrosis (PO) (Combination therapy) in USA before January 2017
  • 08 Jan 2017 VX 440 receives Fast Track designation for Cystic fibrosis (PO) (Monotherapy, In volunteers) in USA before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top